Athira Pharma (NASDAQ:LONA) Stock Rating Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Athira Pharma (NASDAQ:LONA – Free Report) from a hold rating to a sell rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

LONA has been the topic of several other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Athira Pharma in a research report on Wednesday, November 4th. Mizuho reduced their target price on shares of Athira Pharma from $13.00 to $12.00 and set an “outperform” rating for the company in a report on Thursday. Finally, Citizens Jmp decreased their target price on shares of Athira Pharma from $17.00 to $16.00 and set a “market outperform” rating for the company in a research report on Tuesday, November 17th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Athira Pharma presently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Check Out Our Latest Stock Analysis on LONA

Athira Pharma Trading Down 17.6%

LONA stock opened at $2.03 on Friday. The company has a 50-day moving average price of $4.88 and a 200 day moving average price of $7.48. Athira Pharma has a 12 month low of $1.91 and a 12 month high of $14.21. The stock has a market cap of $19.02 million, a PE ratio of -0.48 and a beta of 1.90.

Athira Pharma (NASDAQ:LONA – Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.27). Sell-side analysts forecast that Athira Pharma will post -3.17 EPS for the current year.

About Athira Pharma

(Get Free Report)

Athira Pharma is a clinical-stage biopharmaceutical company based in Bothell, Washington, that focused on developing treatments for neurodegenerative diseases and other conditions affecting the brain. Its research centered on the hepatocyte growth factor (HGF) and MET biological system, which is involved in neuronal health and repair. The company’s pipeline included fosgonimeton, an investigational therapy studied for Alzheimer’s disease and dementia associated with Parkinson’s disease, as well as ATH-1105, a small-molecule candidate investigated for amyotrophic lateral sclerosis.

Featured Articles

Analyst Recommendations for Athira Pharma (NASDAQ:LONA)

Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.